Optimized AAV design, precision engineering and scalable production
We custom-build AAV plasmids to increase quality and titre.
We guide smooth, scalable transition from our transient production systems to our stable AAV packaging and producer cell lines.
We support scalable custom AAV production in bioreactor models using our proprietary HEK293 cell production platform.
AAV at the edge of impossible
OXGENE helps solve the greatest challenge of gene therapy: scaling up. We produce large quantities of functional AAV particles in a scalable manufacturing system. Our early-access partnerships for AAV packaging cell line development mean we provide a seamless path from AAV design to the clinic.
We’ve developed and optimized a 3-plasmid AAV system with a new, evolved breed of recombinant AAV Rep-Cap vector, reduced reverse genomic packaging, and an inducible expression system that enables stable cell line development in HEK-293 cells. We use this to generate high-quality, high-yield AAV in scalable manufacturing workflows, all based upon our GMP-compliant HEK293-isolated clonal cell line.
Our manufacturing systems aim to transition the industry from non-scalable adherent AAV production to scalable, efficient and stable systems that reduce overall development costs, lower manufacturing costs, and facilitate cost effective treatments for patients.
Our AAV production platform simplifies the genetic engineering process to reduce the timeframe between upstream production and market approval.
We are very excited to begin this collaboration [with OXGENE]. It’s one of many vital steps that we are taking to meet the demand for a broadening range of gene therapies. We hope that our approach will lead to quicker development of effective new therapies for patients.